# Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

> **NCT02357420** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 393 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetes Mellitus Complications
- Gastroparesis

## Interventions

- **DRUG:** Relamorelin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02357420
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-29
- **Primary completion:** 2016-06-09
- **Final completion:** 2016-06-09
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02357420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02357420, "Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02357420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*